[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
We evaluated risk factors for elevation of liver function test values after administration of fenofibrate to 45 hyperlipidemic patients. The effects of 23 factors of physical examinations, clinical laboratory test values, and the background of the patients on the elevation of liver function test values were analyzed by the logistic regression method. The increase of the values of liver function tests was found to be correlated with BMI, serum levels of triglycerides, and ALP before therapy, especially sex, serum gamma-GTP level before therapy and reduced serum triglyceride levels. These results suggest that caution must be exercised to avoid liver dysfunction in patients treated with fenofibrate.
Hayakawa
Toru
T
Department of Pharmacy, Sapporo Kosei Hospital, Higashi-8, Kita-3, Chuo-ku, Sapporo, Hokkaido 060-0033, Japan. hayakawa@hokuyakudai.ac.jp
Hayashi
Akemi
A
Miyakawa
Maiko
M
Shimoyama
Koichi
K
Sekiya
Shigeru
S
Sekiguchi
Masatomo
M
Inotsume
Nobuo
N
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015992:Body Mass Index; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008111:Liver Function Tests; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood; D005723:gamma-Glutamyltransferase / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D011345:Fenofibrate